Skip to main content

Table 4 Subgroup analysis of PFS of patients treated with metronomic vs. conventional zoledronic acid

From: Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

Clinical and biochemical factor HR (95% CI) P
DFI (year) > 2 1.318 (0.660-2.630) 0.437
  ≤ 2 3.455 (1.043-11.445) 0.043
ER status + 1.036 (0.504-2.130) 0.922
  - 4.178 (1.130-15.450) 0.032
Lymph node status ≤ 3 1.340 (0.699-2.568) 0.378
  > 3 2.093 (0.636-6.893) 0.224
Numbers of previous chemotherapy ≤ 2 1.107 (0.586-2.093) 0.754
  > 2 11.440 (1.348-97.069) 0.025
Baseline CEA (ug/L) ≤ 10 1.281 (0.644-2.549) 0.481
  > 10 3.927 (1.179-13.079) 0.026
Baseline CA 15-3 (U/mL) ≤ 25 0.762 (0.258-2.251) 0.623
  > 25 2.087 (1.056-4.122) 0.034
Baseline NTx (nM BCE) ≤ 18 0.945 (0.399-2.241) 0.898
  > 18 2.520 (1.141-5.566) 0.022
Baseline VEGF (pg/mL) ≤ 500 2.337 (0.522-10.468) 0.267
  > 500 1.186 (0.546-2.573) 0.667
VEGF (3 months after intervention) (pg/mL) ≤ 500 0.834 (0.340-2.046) 0.692
  > 500 1.596 (0.619-4.115) 0.333